A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of NBI-5788 [tiplimotide] in Patients With Relapsing Multiple Sclerosis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of NBI-5788 [tiplimotide] in Patients With Relapsing Multiple Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2008

At a glance

  • Drugs Tiplimotide (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MS-APL
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 18 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top